- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | AB&B BIO-TECH-B (02627): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.03. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - ENTERING INTO OF STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| AB&B BIO-TECH Aktie jetzt für 0€ handeln | |||||
| 11.03. | HSI Closes at 25,898, Down 61 pts; HSTI Closes at 5,054, Down 5 pts; CATL Up over 9%; 160 HEALTH, AB&B BIO-TECH-B, GOFINTECH QUANT, KINETIC DEV, YANCOAL AUS Hit New Highs; Market Turnover Rises | 4 | AASTOCKS | ||
| 11.03. | HSI Closes Midday at 25,981, Up 21 pts; HSTI Closes Midday at 5,073, Up 13 pts; GEELY AUTO Up over 8%; 160 HEALTH, AB&B BIO-TECH-B, GOFINTECH QUANT, CHUANGXIN IND, JIAXIN INTL RES Hit New Highs | 53 | AASTOCKS | ||
| 10.03. | HSI Up 551 pts; HSTI Up 118 pts; TENCENT Up over 7%; BABA Up over 3%; XUNCE, HAIXI PHARMA, AB&B BIO-TECH-B, JIAXIN INTL RES, LINGBAOGOLD-100 Hit New Highs; Market Turnover Rises | 16 | AASTOCKS | ||
| 04.03. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY U.S. FDA FOR MRNA MPOX VACCINE | 1 | HKEx | ||
| 26.02. | AB&B BIO-TECH-B (02627): PROFIT ALERT - EXPECTED REDUCTION IN LOSS | 2 | HKEx | ||
| 16.02. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX | 3 | HKEx | ||
| 30.01. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - APPROVAL OF OUR APPLICATION FOR TRIVALENT SUBUNIT INFLUENZA VACCINE BY THE NMPA | - | HKEx | ||
| 12.01. | AB&B BIO-TECH-B (02627): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) RESIGNATION OF BOARD SECRETARY AND JOINT COMPANY SECRETARY | - | HKEx | ||
| 23.12.25 | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 23.12.25 | AB&B BIO-TECH-B (02627): (1) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND ... | 1 | HKEx | ||
| 08.12.25 | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE III CLINICAL TRIAL FOR LYOPHILIZED HUMAN RABIES VACCINE (HUMAN DIPLOID CELL) | 1 | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): FORM OF PROXY FOR THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 TO BE HELD ON TUESDAY, DECEMBER 23, 2025 AND ANY ADJOURNMENT ... | 1 | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): (1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR (2) RE-APPOINTMENT OF AUDITORS AND (3) NOTICE OF EGM | 4 | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 | - | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): (I) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (II) NOMINATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (III) CHANGE ... | 1 | HKEx | ||
| 13.11.25 | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I CLINICAL TRIAL FOR ADJUVANTED QUADRIVALENT SUBUNIT INFLUENZA VACCINE AND ADJUVANTED ... | 1 | HKEx | ||
| 15.10.25 | AB&B BIO-TECH-B (02627): INSIDE INFORMATION - APPLICATION FOR THE H SHARE FULL CIRCULATION BY THE COMPANY | - | HKEx | ||
| 29.09.25 | AB&B BIO-TECH-B (02627): NOTIFICATION LETTER TO NON-REGISTERED HOLDERS OF H SHARES AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE ... | - | HKEx |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARTELO BIOSCIENCES | 10,510 | +229,47 % | Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen | |
| QIAGEN | 33,900 | -3,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,250 | +11,58 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,980 | -1,19 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| ONCONETIX | 1,890 | -41,30 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1US98386D3070 XTL Biopharmaceuticals... ► Artikel lesen | |
| ARCELLX | 114,56 | -0,07 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| BIONTECH | 74,50 | -1,84 % | Biotech-Werte im Check: Warum Emyria, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| APOGEE THERAPEUTICS | 77,85 | -0,74 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,890 | -3,43 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 78,18 | -2,82 % | Kymera Therapeutics, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 38,900 | -0,71 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| CG ONCOLOGY | 64,67 | -2,90 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| STRUCTURE THERAPEUTICS | 45,900 | -0,80 % | Wolfe Research initiates Structure Therapeutics stock rating at Peerperform | ||
| ALUMIS | 24,840 | -5,62 % | Taking a Page From Cancer Drugs, Autoimmune Biotech Alumis Aims for Precision Immunology | ||
| ZENAS BIOPHARMA | 18,275 | -17,53 % | Zenas BioPharma Prices $300M Capital Raise in Dual Offering |
Das Unternehmen AB&B BIO-TECH CO LTD JS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AB&B BIO-TECH CO LTD JS finden Sie auf Wallstreet Online.